ADC Bio Invests $11M in Bioconjugation Facility

Will provide capabilities and R&D technical services from process development through to manufacturing

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ADC Biotechnology is investing $11 million to build a bioconjugation facility at its new site in Deeside, North Wales, UK. The new facility will provide a suite of capabilities ranging from R&D technical services, quality control, QA, warehousing, and process development through to manufacturing. As a result, ADC Bio will have free capacity to upscale from early clinical phases into late phase and commercial manufacturing within the new facility.   The 6,500m2 facility – scheduled to be op...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters